ThioLogics is a UCL spin-out company developing a technology platform that will enable the homogeneous modification of native polypeptides. Specifically, we have discovered groundbreaking technology, based on Next Generation Maleimides, that allows the selective bridging and functionalisation of disulfide bonds in antibodies, proteins and peptides. We are particularly focused on the application of our technology to the assembly of homogeneous antibody conjugates. Technology that will allow modification of antibodies to yield homogeneous products is highly desirable. In particular, it has been demonstrated that homogeneous antibody drug conjugates (ADCs) have a greatly improved therapeutic index over analogous heterogeneous formulations. Introducing greater homogeneity into antibody conjugates will also greatly simplify process and development issues, thereby reducing costs. For further information, please visit www.thiologics.com
View Top Employees from ThioLogicsWebsite | http://www.thiologics.com |
Revenue | $6 million |
Employees | 3 (1 on RocketReach) |
Phone | +44 20 7679 9000 |
Industry | Biotechnology Research, Business Services General, Business Services |
Competitors | Aptum Biologics Ltd., Fusion Antibodies, IMMUNE SYSTEMS LIMITED, IONTAS, SB Drug Discovery |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies |
Looking for a particular ThioLogics employee's phone or email?
The ThioLogics annual revenue was $6 million in 2023.
James Baker is the Co-Founder of ThioLogics.
1 people are employed at ThioLogics.
The NAICS codes for ThioLogics are [54171, 54, 541714, 5417, 541].
The SIC codes for ThioLogics are [873, 87].